These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27161763)

  • 1. Validation of a 15-gene hypoxia classifier in head and neck cancer for prospective use in clinical trials.
    Toustrup K; Sørensen BS; Metwally MA; Tramm T; Mortensen LS; Overgaard J; Alsner J
    Acta Oncol; 2016; 55(9-10):1091-1098. PubMed ID: 27161763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck.
    Toustrup K; Sørensen BS; Lassen P; Wiuf C; Alsner J; Overgaard J;
    Radiother Oncol; 2012 Jan; 102(1):122-9. PubMed ID: 21996521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
    Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Linge A; Lohaus F; Löck S; Nowak A; Gudziol V; Valentini C; von Neubeck C; Jütz M; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Krause M; Baumann M;
    Radiother Oncol; 2016 Dec; 121(3):364-373. PubMed ID: 27913065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells.
    Sørensen BS; Busk M; Olthof N; Speel EJ; Horsman MR; Alsner J; Overgaard J
    Radiother Oncol; 2013 Sep; 108(3):500-5. PubMed ID: 23953409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).
    Thomson DJ; Slevin NJ; Baines H; Betts G; Bolton S; Evans M; Garcez K; Irlam J; Lee L; Melillo N; Mistry H; More E; Nutting C; Price JM; Schipani S; Sen M; Yang H; West CM;
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):771-782. PubMed ID: 38072326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of prognostic and predictive value of CA IX in radiotherapy of squamous cell carcinoma of the head and neck with known modifiable hypoxia: an evaluation of the DAHANCA 5 study.
    Eriksen JG; Overgaard J;
    Radiother Oncol; 2007 Jun; 83(3):383-8. PubMed ID: 17543403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer.
    Toustrup K; Sørensen BS; Nordsmark M; Busk M; Wiuf C; Alsner J; Overgaard J
    Cancer Res; 2011 Sep; 71(17):5923-31. PubMed ID: 21846821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
    Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
    Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer.
    Lassen P; Eriksen JG; Hamilton-Dutoit S; Tramm T; Alsner J; Overgaard J;
    Radiother Oncol; 2010 Jan; 94(1):30-5. PubMed ID: 19910068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptomic and epigenetic landscape of nimorazole-enhanced radiochemotherapy in head and neck cancer.
    Besso MJ; Bitto V; Koi L; Wijaya Hadiwikarta W; Conde-Lopez C; Euler-Lange R; Bonrouhi M; Schneider K; Linge A; Krause M; Baumann M; Kurth I
    Radiother Oncol; 2024 Oct; 199():110348. PubMed ID: 38823583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of a 15-gene hypoxia classifier in oropharyngeal cancer treated with accelerated chemoradiotherapy.
    Deschuymer S; Sørensen BS; Dok R; Laenen A; Hauben E; Overgaard J; Nuyts S
    Strahlenther Onkol; 2020 Jun; 196(6):552-560. PubMed ID: 32080773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma.
    Betts GN; Eustace A; Patiar S; Valentine HR; Irlam J; Ramachandran A; Merve A; Homer JJ; Möller-Levet C; Buffa FM; Hall G; Miller CJ; Harris AL; West CM
    Eur J Cancer; 2013 Jan; 49(1):156-65. PubMed ID: 22951015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).
    Metwally MA; Frederiksen KD; Overgaard J
    Acta Oncol; 2014 May; 53(5):654-61. PubMed ID: 24328536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
    Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the population pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial.
    Hassan Metwally MA; Jansen JA; Overgaard J
    Clin Oncol (R Coll Radiol); 2015 Mar; 27(3):168-75. PubMed ID: 25530485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy quality assurance of the IAEA-HypoX trial of the accelerated radiotherapy in the treatment of head and neck squamous cell carcinoma with or without the hypoxic radiosensitizer nimorazole.
    Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Overgaard J; Grau C
    Acta Oncol; 2015; 54(9):1673-7. PubMed ID: 26397148
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85.
    Overgaard J; Hansen HS; Overgaard M; Bastholt L; Berthelsen A; Specht L; Lindeløv B; Jørgensen K
    Radiother Oncol; 1998 Feb; 46(2):135-46. PubMed ID: 9510041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.